Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program

The Defense Health Agency Aurora, on behalf of the TRICARE Management Activity, is soliciting quotes for pharmaceutical agents to support the Department of Defense (DoD) Pharmacy Uniform Formulary. Pursuant to 10 U.S.C. § 1074g and 32 CFR Section 199.21, the DoD Pharmacy and Therapeutics Committee evaluates the clinical and cost effectiveness of drugs within specific therapeutic classes to determine their selection and cost-sharing classification. This solicitation specifically targets oncological agents for myelofibrosis, including Inrebic, Jakafi, Ojjaara, and Vonjo. The government may award Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements based on the final formulary decisions.

This requirement is identified under solicitation number HT9402-26-Q-9101 and is classified under NAICS 325412 Pharmaceutical Preparation Manufacturing and PSC 6505 Drugs and Biologicals. Performance is centered in San Antonio, Texas, with a response deadline of January 16, 2026. Tracy Banks serves as the primary point of contact for this notice. The solicitation package includes eight attachments, such as the Request for Quotation (RFQ), various price lists, and amendments updated through January 8, 2026.

The procurement process involves a pre-quotation teleconference held on November 20, 2025, to discuss instructions and deadlines for the submission of quotes. The resulting agreements will facilitate the integration of selected agents into the Military Health System pharmacy benefits program, categorizing them as generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary. All administrative procedures for participation, including reporting requirements for the February 2026 Pharmacy and Therapeutics Committee meeting, are detailed within the RFQ and its associated appendices.